AEON Biopharma Files 8-K
Ticker: AEON · Form: 8-K · Filed: Jul 9, 2024 · CIK: 1837607
Sentiment: neutral
Topics: 8-K, company-update
TL;DR
AEON Biopharma filed an 8-K on July 9th, just a standard update.
AI Summary
AEON Biopharma, Inc. filed an 8-K on July 9, 2024, to report other events. The company, formerly known as Priveterra Acquisition Corp. until December 22, 2020, is incorporated in Delaware and headquartered in Irvine, California.
Why It Matters
This filing indicates a routine update or event for AEON Biopharma, Inc., providing transparency to investors about the company's operational status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain information indicating significant new risks.
Key Players & Entities
- AEON Biopharma, Inc. (company) — Registrant
- Priveterra Acquisition Corp. (company) — Former company name
- July 9, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Irvine, CA (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for AEON Biopharma, Inc.?
The 8-K filing on July 9, 2024, is to report 'Other Events'.
When did AEON Biopharma, Inc. change its name from Priveterra Acquisition Corp.?
The company changed its name from Priveterra Acquisition Corp. on December 22, 2020.
In which state is AEON Biopharma, Inc. incorporated?
AEON Biopharma, Inc. is incorporated in Delaware.
What is the business address of AEON Biopharma, Inc.?
The principal executive offices are located at 5 Park Plaza, Suite 1750, Irvine, CA 92614.
What is the SIC code for AEON Biopharma, Inc.?
The Standard Industrial Classification (SIC) code for AEON Biopharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 474 words · 2 min read · ~2 pages · Grade level 13.3 · Accepted 2024-07-09 08:06:36
Key Financial Figures
- $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share AEON NYSE Ameri
Filing Documents
- aeon-20240709x8k.htm (8-K) — 33KB
- 0001837607-24-000077.txt ( ) — 161KB
- aeon-20240709.xsd (EX-101.SCH) — 4KB
- aeon-20240709_def.xml (EX-101.DEF) — 3KB
- aeon-20240709_lab.xml (EX-101.LAB) — 17KB
- aeon-20240709_pre.xml (EX-101.PRE) — 10KB
- aeon-20240709x8k_htm.xml (XML) — 5KB
01. Other Events
Item 8.01. Other Events. On July 9, 2024, AEON Biopharma, Inc. (the "Company") announced a strategic reprioritization to pursue a 351(k) biosimilar regulatory pathway for its lead candidate, ABP-450, using AbbVie Inc.'s product BOTOX as the reference product, and plans to advance a single pivotal clinical development study in cervical dystonia for ABP-450 using this pathway, following a meeting with the United States Food and Drug Administration ("FDA"). A successful Phase 3 comparative study in cervical dystonia would potentially provide the necessary clinical data to support a determination that ABP-450 is highly similar to the reference product for up to all of its eight currently approved and future therapeutic indications. The Company also announced plans to discuss the proposed biosimilar pathway with the FDA during a Biosimilar Initial Advisory Meeting currently scheduled for the third quarter of 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AEON Biopharma, Inc. Date: July 9, 2024 By: /s/ Marc Forth Marc Forth Chief Executive Officer